How big is the Anti-obesity Drugs Market?

The Anti-obesity Drugs Market size is expected to reach USD 8.03 billion in 2024 and grow at a CAGR of 15.37% to reach USD 16.41 billion by 2029. Read More

What is the current Anti-obesity Drugs Market size?

In 2024, the Anti-obesity Drugs Market size is expected to reach USD 8.03 billion. Read More

Who are the key players in Anti-obesity Drugs Market?

Vivus, F Hoffmann-La Roche AG, GlaxoSmithKline PLC, Novo Nordisk AS and Currax Pharmaceuticals LLC are the major companies operating in the Anti-obesity Drugs Market. Read More

Which is the fastest growing region in Anti-obesity Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Anti-obesity Drugs Market?

In 2024, the North America accounts for the largest market share in Anti-obesity Drugs Market. Read More

What years does this Anti-obesity Drugs Market cover, and what was the market size in 2023?

In 2023, the Anti-obesity Drugs Market size was estimated at USD 6.80 billion. The report covers the Anti-obesity Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Anti-obesity Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Anti-obesity Drugs Market Share

Statistics for the 2023 & 2024 Anti-obesity Drugs market share, created by Mordor Intelligence™ Industry Reports. Anti-obesity Drugs share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Anti-obesity Drugs Industry

The anti-obesity drug market is moderated due to the presence of companies operating globally and regionally. The competitive landscape includes an analysis of a few international as well as local companies that hold a significant market share and are well known, including GlaxoSmithKline PLC, Novo Nordisk AS, Pfizer Inc., F. Hoffmann-La Roche AG, and Bayer AG.